Concord Medical Services Holdings Limited, a healthcare provider specializing in cancer care, research and prevention by operating a network of medically advanced comprehensive cancer hospitals and standalone radiotherapy and diagnostic imaging centers in China, has announced that its Guangzhou Concord Cancer Center (GCCC), which is certified as a tertiary specialty hospital by the National Health Commission, is now in operation. This has marked a major milestone for the Company.

Situated in Sino-Singapore Guangzhou Knowledge City, Guangzhou's newest modern development district, GCCC is a specialty cancer hospital and is built in strict compliance with domestic tertiary hospital standards, the highest domestic standards for medical institutions.

As a support institution of the Society of Tumor Microenvironment, China Anti-Cancer Association and a member of the Union for International Cancer Control, GCCC is equipped with the state-of-the-art medical technologies, including the Probeam proton system, whose superconducting cyclotron is one of the most powerful particle accelerators available today to treat cancer with exceptional precision.

Utilizing the cutting-edge medical technologies, GCCC aims to and is committed to providing patients with multi-disciplinary healthcare services and patient-centered experience in strict compliance with international standards for cancer diagnosis and treatment.

Concord Medical aims to build an internationalized cancer center specializing in clinical diagnosis and treatment, cancer prevention, medical research, specialist training and remote medical consultation in Guangzhou to benefit all cancer patients.

GCCC is operated by Meizhong Jiahe Medical Science & Technology Development Group Co., Ltd. (Meizhong Jiahe), a subsidiary of Concord Medical, and is established in cooperation with top international and domestic medical institutions. Constructed since 2010, GCCC is now able to provide patients with full-process medical services from cancer prevention to recovery.